CGTLive’s Weekly Rewind – August 25, 2023


Review top news and interview highlights from the week ending August 25, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. CAR-M/Pembrolizumab Trial Doses First Patient With HER2-Overexpressing Solid Tumors

Initial data from the combination substudy are expected in the second half of 2023.

2. Robert J. Hariri, MD, PhD, on the Importance of Placental-Derived Stem Cells in Cell Therapy

The founder, chairman, and CEO of Celularity discussed the advantages of cells derived from umbilical cord blood versus other sources of cells for cell therapies.

3. Gene Therapy Improves Grade 2/3 Xerostomia Symptoms

Participants treated both unilaterally or bilaterally reported clinically meaningful improvements on GRCQ and XQ scale scores.

4. Thomas Povsic, MD, PhD, on Addressing Unmet Needs in Refractory Angina With Gene Therapy

The interventional cardiologist and professor, Duke University School of Medicine, discussed how XC001 could improve outcomes for patients with refractory angina.

5. Gaucher Disease Type 1 Gene Therapy Trial Proceeds to Dose Second Cohort

The company announced that it had completed dosing in the first cohort of the GALILEO-1 trial of FLT201.

Related Videos
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
Aimee C. Talleur, MD, a physician at St. Jude Children’s Research Hospital
N. Nora Bennani, MD
David Porter, MD
Heather Lau, MD, MS, the executive director of global clinical development at Ultragenyx Pharmaceutical
© 2024 MJH Life Sciences

All rights reserved.